Actively helping customers, employees and the global community during the coronavirus SARS-CoV-2 outbreak.  Learn more >>

Biotinylated goat anti-rabbit IgG (H+L)

Image of HeLa cells. HeLa cells were incubated with (Tubulin+) or without (Control) rabbit anti-tubulin, followed by biotinylated goat anti-rabbit IgG (H&L) (Cat# 16794) stain, and finally visualized with iFluor® 555-streptavidin conjugate (Cat# 16959).
Image of HeLa cells. HeLa cells were incubated with (Tubulin+) or without (Control) rabbit anti-tubulin, followed by biotinylated goat anti-rabbit IgG (H&L) (Cat# 16794) stain, and finally visualized with iFluor® 555-streptavidin conjugate (Cat# 16959).
Ordering information
Price ()
Catalog Number16794
Unit Size
Find Distributor
Additional ordering information
Telephone1-408-733-1055
Fax1-408-733-1304
Emailsales@aatbio.com
InternationalSee distributors
ShippingStandard overnight for United States, inquire for international
Physical properties
Molecular weight150000
SolventWater
Storage, safety and handling
H-phraseH303, H313, H333
Hazard symbolXN
Intended useResearch Use Only (RUO)
R-phraseR20, R21, R22
StorageFreeze (< -15 °C); Minimize light exposure
UNSPSC12171501

OverviewpdfSDSpdfProtocol


Molecular weight
150000
Many biotin molecules can be conjugated to a secondary antibody with the additional advantage of streptavidin having a high affinity for biotin. Through this amplification step and having the streptavidin bound to labels such as HRP or fluorescent probes, proteins which are expressed at low levels are more likely to be detected. For most assays, the biotin-labeled secondary antibody is added first, sequentially followed by the streptavidin conjugated to a label e.g. HRP.

Calculators


Common stock solution preparation

Table 1. Volume of Water needed to reconstitute specific mass of Biotinylated goat anti-rabbit IgG (H+L) to given concentration. Note that volume is only for preparing stock solution. Refer to sample experimental protocol for appropriate experimental/physiological buffers.

0.1 mg0.5 mg1 mg5 mg10 mg
1 mM666.667 nL3.333 µL6.667 µL33.333 µL66.667 µL
5 mM133.333 nL666.667 nL1.333 µL6.667 µL13.333 µL
10 mM66.667 nL333.333 nL666.667 nL3.333 µL6.667 µL

Molarity calculator

Enter any two values (mass, volume, concentration) to calculate the third.

Mass (Calculate)Molecular weightVolume (Calculate)Concentration (Calculate)Moles
/=x=

Citations


View all 4 citations: Citation Explorer
Overexpression of CXCR2 predicts poor prognosis in patients with colorectal cancer.
Authors: Zhao, Jingkun and Ou, Baochi and Feng, Hao and Wang, Puxiongzhi and Yin, Shuai and Zhu, Congcong and Wang, Shenjie and Chen, Chun and Zheng, Minhua and Zong, Yaping and others, undefined
Journal: Oncotarget (2017)
Cadherin-12 enhances proliferation in colorectal cancer cells and increases progression by promoting EMT
Authors: Ma, Junjun and Zhao, Jingkun and Lu, Jun and Wang, Puxiongzhi and Feng, Hao and Zong, Yaping and Ou, Baochi and Zheng, Minhua and Lu, Aiguo
Journal: Tumor Biology (2016): 1--12
Transplantation of RADA16-BDNF peptide scaffold with human umbilical cord mesenchymal stem cells forced with CXCR4 and activated astrocytes for repair of traumatic brain injury
Authors: Shi, W and Huang, CJ and Xu, XD and Jin, GH and Huang, RQ and Huang, JF and Chen, YN and Ju, SQ and Wang, Y and Shi, YW and others, undefined
Journal: Acta Biomaterialia (2016): 247--261
The migration and differentiation of hUC-MSCsCXCR4/GFP encapsulated in BDNF/chitosan scaffolds for brain tissue engineering
Authors: Huang, Chuanjun and Zhao, Longxiang and Gu, Jun and Nie, Dekang and Chen, Yinan and Zuo, Hao and Huan, Wei and Shi, Jinlong and Chen, Jian and Shi, Wei
Journal: Biomedical Materials (2016): 035004

References


View all 191 references: Citation Explorer
Antiprothrombin antibodies in a patient with secondary antiphospholipid syndrome and bleeding
Authors: Gonzalez Leon R, Garcia Hern and ez FJ, Castillo Palma MJ, Sanchez Roman J.
Journal: Med Clin (Barc) (2011): 668
Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers
Authors: Waterhouse BR, Gijsen M, Barber PR, Tullis ID, Vojnovic B, Kong A.
Journal: Oncotarget (2011): 728
Falsely elevated tacrolimus levels caused by immunoassay interference secondary to beta-galactosidase antibodies in an infected liver transplant recipient
Authors: Knorr JP, Grewal KS, Balasubramanian M, Young N, Zaki R, Khanmoradi K, Araya V, Ortiz J.
Journal: Pharmacotherapy (2010): 954
Prevalence of anti-Epstein-Barr virus antibodies in children and adolescents with secondary immunodeficiency
Authors: Buckova A., undefined
Journal: Epidemiol Mikrobiol Imunol (2010): 133
Analysis of the effectiveness of reused primary and secondary antibodies in Western blotting analysis
Authors: Boonrod K, Roth B, Leong Ngar S, Krczal G.
Journal: Anal Biochem (2010): 124
Nanosilver-doped DNA polyion complex membrane for electrochemical immunoassay of carcinoembryonic antigen using nanogold-labeled secondary antibodies
Authors: Wu W, Yi P, He P, Jing T, Liao K, Yang K, Wang H.
Journal: Anal Chim Acta (2010): 126
Three siblings with self-resolving congenital hyperthyrotropinaemia secondary to thyrotropin receptor blocking antibodies
Authors: Azzopardi P, Forrester M, Ehtisham S.
Journal: J Paediatr Child Health (2010): 439
Double-blotting: a solution to the problem of nonspecific binding of secondary antibodies in immunoblotting procedures
Authors: Lasne F., undefined
Journal: Methods Mol Biol (2009): 213
Parkinsonism/dystonia syndrome secondary to multiple sclerosis with anti-basal-ganglia antibodies
Authors: Delgado S, Baez S, Singer C, Sengun C, Sheremata WA, Papapetropoulos S.
Journal: Mov Disord (2009): 309
Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing
Authors: Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K.
Journal: Clin Neuropharmacol (2009): 213